^
Association details:
| Biomarker: | VEGFA expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Published date:
10/07/2020
Excerpt:
The 5-factor PFS-CBS was comprised of HGF, MIG, IL-18BP, IL-18, and ANG-2 and the 5-factor OS-CBS included TIMP-1, M-CSF, IL-18BP, ANG-2 and VEGF….Multivariate Cox regression analyses indicated that the CBS-high group was predictive of a longer PFS and OS with lenvatinib-plus-everolimus versus lenvatinib (Pinteraction = 0.0070 and Pinteraction = 0.0377, respectively) but not versus everolimus (Pinteraction = 0.2297 and Pinteraction = 0.2125, respectively).
Secondary therapy:
everolimus
DOI:
10.1038/s41416-020-01092-0
Trial ID:
